1 Here we describe a 'catch-and-release' mechanism that am
2 Here we describe a broadly applicable technique called '
3 Here we describe a cubic host obtained from the self-ass
4 Here we describe a detailed protocol based on covalent b
5 Here we describe a detailed protocol that describes how
6 Here we describe a discovery platform that can identify
7 Here we describe a dual inhibitor of the bromodomain and
8 Here we describe a flow cytometry workflow to determine
9 Here we describe a flow system comprised of two function
10 Here we describe a form of metabolism linking anoxygenic
11 Here we describe a GWAS using a highly multiplexed aptam
12 Here we describe a long-sought route through ribose amin
13 Here we describe a measurement platform that allows for
14 Here we describe a mechanism for transmitting a chemical
15 Here we describe a medicinal chemistry program starting
16 Here we describe a method - Freestyle Fluidics - that ov
17 n oncogenes under tissue-specific promoters,
here we describe a method that allows for the precise op
18 Here we describe a microfluidic DNA preconcentration tec
19 Here we describe a microfluidics-based strategy to spin
20 Here we describe a molecular device that couples CRISPR-
21 Here we describe a molecular system that can be programm
22 Here we describe a multinational drug discovery programm
23 Here we describe a natural experiment involving deterior
24 Here we describe a new member of this group, Xandarella
25 Here we describe a new method for neuronal labelling by
26 Here we describe a new mouse strain, in which human inte
27 Here we describe a new software tool, RNAModMapper (RAMM
28 Here we describe a new, exquisitely three-dimensionally
29 Here we describe a novel homogeneous fluorescence intens
30 Here we describe a novel osteoadsorptive bisphosphonate-
31 Here we describe a novel real-time quantitative PCR (qPC
32 Here we describe a panel of genetic screens to identify
33 Here we describe a parasite-specific transcription facto
34 Here we describe a phosphoproteomics workflow to examine
35 Here we describe a physiologically relevant model for st
36 Here we describe a platform for identifying target-bindi
37 Here we describe a previously unappreciated contribution
38 Here we describe a protocol to generate expandable and m
39 Here we describe a rapid, simple and versatile Free-of-A
40 Here we describe a reporter cell-based assay to quantify
41 Here we describe a revised PHI-base Version 4 data platf
42 Here we describe a role for the RNA processing factors T
43 Here we describe a scheme for protecting solid-state qub
44 Here we describe a simple and powerful method involving
45 Here we describe a simple and reproducible method to gen
46 Here we describe a subset of tumor-infiltrating CD8(+) T
47 Here we describe a systematic study of cytosine-rich DNA
48 Here we describe a technique that improves the spatiotem
49 Here we describe a versatile, functional pipeline and ap
50 Here, we describe a 3.6 A single-particle cryo-EM recons
51 Here, we describe a 3D printed inexpensive open source a
52 Here, we describe a case of a presplenectomized 30-year-
53 Here, we describe a combined biological/enzymatic synthe
54 Here, we describe a complementary gas chromatography-ele
55 Here, we describe a computational method, dubbed CAPE, w
56 Here, we describe a CRISPR affinity purification in situ
57 Here, we describe a CRISPR-based system that uses pairs
58 Here, we describe a cross-sectional study where subjects
59 Here, we describe a designed dominant negative termed A-
60 Here, we describe a dissociation method that uses a prot
61 Here, we describe a family with Liddle syndrome due to a
62 Here, we describe a function for autophagy in germline s
63 Here, we describe a gene expression model, which is repr
64 Here, we describe a general approach for predicting pept
65 Here, we describe a general approach that we developed t
66 Here, we describe a general inverse design algorithm for
67 Here, we describe a general method for using radiolabele
68 Here, we describe a generalizable platform to create dua
69 Here, we describe a generic method to separate the indiv
70 Here, we describe a high-throughput method for rapid ide
71 Here, we describe a highly parallel, low-cost method for
72 Here, we describe a homeostatic regulatory circuit that
73 Here, we describe a hybrid platform combining common ana
74 Here, we describe a machine learning approach, called HI
75 Here, we describe a materials-based approach whereby app
76 Here, we describe a mechanism optimizing the performance
77 Here, we describe a mechanism that accounts for the abil
78 Here, we describe a method for the unbiased, in vivo sel
79 Here, we describe a method that allows temporal control
80 Here, we describe a method that drastically improves int
81 Here, we describe a molecular toolkit for rapid preparat
82 Here, we describe a mouse strain lacking the E3 ubiquiti
83 Here, we describe a new methodology for a rapid and modu
84 Here, we describe a new mouse model suitable for such ri
85 Here, we describe a new recombinant PRV expressing a car
86 Here, we describe a new role for the ATP-dependent helic
87 Here, we describe a novel antiapoptotic mechanism in vas
88 Here, we describe a novel approach to stereoselective sy
89 Here, we describe a novel cAMP/PKA signalling domain loc
90 Here, we describe a novel injury assay in adult Drosophi
91 Here, we describe a novel method based on intronic MiMIC
92 Here, we describe a novel method that integrates the cov
93 Here, we describe a novel method to quantitate and asses
94 Here, we describe a novel temporal mechanism of topograp
95 Here, we describe a photoredox-assisted catalytic system
96 Here, we describe a platform for phenotyping variant lib
97 Here, we describe a proof-of-concept for new methodology
98 Here, we describe a proteomics approach that identifies
99 Here, we describe a protocol for generating and expandin
100 Here, we describe a rapid example of dwarfing of a large
101 Here, we describe a rapid method for qualitative label-f
102 Here, we describe a rapid, inexpensive, and portable str
103 Here, we describe a role for CBR1 in metabolism of gluco
104 Here, we describe a role for the CTL of Caulobacter cres
105 Here, we describe a role of AP2 in promoting the mainten
106 Here, we describe a role of LMP1 in EV production that r
107 Here, we describe a scalable, spectroscopic approach tha
108 Here, we describe a screen for transcription factors (TF
109 Here, we describe a second function of PtDd, namely, the
110 Here, we describe a self-contained immunoassay platform
111 Here, we describe a set of tools to rapidly clone and st
112 Here, we describe a similar hypomethylated subtype of lu
113 Here, we describe a single-molecule junction comprising
114 Here, we describe a single-molecule optical-trapping ass
115 Here, we describe a small molecule screen designed to id
116 Here, we describe a structure we refer to as the embryo
117 Here, we describe a structure-guided development of a se
118 Here, we describe a study done in the Lake Superior-Sain
119 Here, we describe a system for differentiating PrrF and
120 Here, we describe a thorough molecular and biochemical a
121 Here, we describe a total of 119 patients with advanced
122 Here, we describe a unique role for the orphan catalytic
123 Here, we describe A-485, a potent, selective and drug-li
124 Here, we described a bnAb lineage targeting the Env V2 a
125 Here, we describe AAV-PHP.eB and AAV-PHP.S, capsids that
126 Here we describe an alternative strategy for Parkinson's
127 Here we describe an antibody mimetic, DARPin K27, which
128 Here we describe an approach to functionally validate id
129 Here we describe an automated computational framework to
130 Here we describe an endogenous Deltaretrovirus, identifi
131 Here we describe an enhanced fluorescence fluctuation im
132 Here we describe an intercalation compound in which the
133 Here we describe an on-demand covalent chemistry to addr
134 Here we describe an optimized protocol for simultaneous
135 Here we describe an smFISH protocol that allows for the
136 Here we describe an unexpected fundamental role for ACKR
137 Here we describe an update of the database.
138 Here, we describe an algorithm that solves the high erro
139 Here, we describe an Amot-dependent complex comprised of
140 Here, we describe an approach to cryogenic photoactivate
141 Here, we describe an automated clustering approach and a
142 Here, we describe an enzymatic/mass spectrometric finger
143 Here, we describe an intellectual disability disorder in
144 Here, we describe an unexpected role of ATR in mitosis.
145 Here, we describe an update of IMG-ABC, which includes C
146 Here we describe and compare tasks that tap into these c
147 Here we describe and computationally validate a framewor
148 Here we describe and functionally characterize a previou
149 Here we described and analyzed a similar phenotype in PO
150 Here, we describe and compare the brains of a day-active
151 Here, we describe and engineer plasmonic substrates base
152 Here, we describe assays capable of distinguishing a var
153 Here, we describe B cell responses to C-PfCSP from Europ
154 Here, we describe bromodomain-containing proteins with d
155 Here, we describe cancer-associated genomic profiles fro
156 Here we describe chemically-driven artificial rotary and
157 Here, we describe ChloroKB, a Web application for visual
158 Here we describe clinicopathologic features of Ebola vir
159 Here we describe '
coincidence-detecting' sensors that se
160 Here, we describe comprehensive adjuvant formulation dev
161 Here, we describe crystal and nuclear magnetic resonance
162 Here we describe DeActs, genetically encoded actin-modif
163 Here, we describe development and characterization of 'S
164 Here we describe emerging findings demonstrating that TS
165 Here we describe evidence of a negative feedback loop, i
166 Here we describe exogenous cycles and endogenous rhythms
167 Here we describe experiments in which we studied binocul
168 Here, we describe for the first time the expression of s
169 Here, we describe functional units, at a cellular level,
170 Here we describe genetic effects on gene expression leve
171 Here we describe genome-engineering based evaluation of
172 Here we describe high-quality draft genomes of these two
173 Here we describe how the endothelial transcription facto
174 Here we describe how to apply CellNet to RNA-seq data an
175 Here, we describe how a specific class of EVs, called mi
176 Here, we describe how F-specific antibodies protect agai
177 Here, we describe how one can apply solid-state NMR, ran
178 Here, we describe how phenotype-to-genotype studies are
179 Here, we describe how plasmonic superlattices-finite-arr
180 Here, we describe how TBI changes the metabolism of esse
181 Here, we describe how to control d by physical confineme
182 Here we describe iterative expansion microscopy (iExM),
183 Here we describe its intercalation by several alkali met
184 Here, we describe Leapfrog, a simple automated BLAST pip
185 Here we describe Mackinac, a Python package that combine
186 Here we describe manipulation of the X. laevis genome us
187 Here we describe methodology permitting fusion gene cons
188 Here, we describe mGluR5 findings in stress disorders, p
189 Here, we describe micro-patterned all-polymer films call
190 Here, we describe molecular force microscopy, leveraging
191 Here, we describe motor cortical changes in a visuomotor
192 Here, we describe mutations in DZIP1L, which encodes DAZ
193 Here we describe networks of capacitating genetic intera
194 Here, we describe NGSCheckMate, a user-friendly software
195 Here, we describe NicE-seq (nicking enzyme assisted sequ
196 Here, we describe Nol12 as a multifunctional RBP with ro
197 Here we describe novel interactions between HSV-1 and th
198 Here we describe our protocol for correlated cryo-fLM, c
199 Here, we describe our approach to monitoring BMT survivo
200 Here, we describe potential biases that arise when ABM a
201 Here, we describe pyocyanin demethylase (PodA), a hither
202 Here we describe RCB-185, a lipophilic prodrug with nano
203 Here we describe "
semisynthetic" pH-sensitive protein co
204 Here we describe sex differentiation in a wild grayling
205 Here we describe SGN-CD19B, a pyrrolobenzodiazepine (PBD
206 Here we describe ShootingStar, a platform for perturbati
207 Here, we describe site-selective, copper-promoted coupli
208 Here, we describe sleep and activity in two neighbouring
209 Here we describe small target-selective neurons in preda
210 Here we describe spectacular extremely expanded, pod-lik
211 Here, we describe structural elements called interface a
212 Here, we describe such a method for elucidating drug res
213 Here, we describe such a method in a 96-well plate forma
214 Here, we describe that low catalyst loadings (0.27 mol %
215 Here we describe the 'Asgard' superphylum, a group of un
216 Here we describe the ability of paclitaxel (PTX), a fron
217 Here we describe the assembly, physical characteristics,
218 Here we describe the correction of the heterozygous MYBP
219 Here we describe the crystal structure of GS-5745.MMP9 c
220 Here we describe the design, discovery, pharmacologic ac
221 Here we describe the development of a point-of-care sens
222 Here we describe the development of a simple, low-cost,
223 Here we describe the efficacy of a HIF-1alpha inhibitor,
224 Here we describe the fabrication of a sub-micrometer ele
225 Here we describe the first phosphorylation event involvi
226 Here we describe the first stages of kidney vascularisat
227 Here we describe the identification of gamma-activated s
228 Here we describe the importance of mRNA translational re
229 Here we describe the interaction of myosin-5B with F-act
230 Here we describe the isolation and characterization of a
231 Here we describe the pathways of host-parasite interacti
232 Here we describe the purification of a neurotoxin precur
233 Here we describe the rational development of new molecul
234 Here we describe the reconstitution of Pol epsilon-depen
235 Here we describe the results in a cohort of 10 stable ki
236 Here we describe the results of a systematic study inves
237 Here we describe the science that supports this novel th
238 Here we describe the sequence assembly and analysis of t
239 Here we describe the shotgun-sequencing of ancient DNA f
240 Here we describe the stabilization of the heaviest 4+ io
241 Here we describe the temporal orchestration of a series
242 Here we describe the tranSMART-XNAT Connector we have de
243 Here we describe the use of a mechanism-based inhibitor,
244 Here we describe the use of Hi-C as a tool for detection
245 Here we describe the use of walking loops in parks and c
246 Here we describe the utility of peptide macrocyclization
247 Here, we describe the capabilities of another activation
248 Here, we describe the central role of inflammatory caspa
249 Here, we describe the circuit architecture of the visual
250 Here, we describe the construction and use of the Activi
251 Here, we describe the construction of supramolecular pol
252 Here, we describe the course and provide resources for d
253 Here, we describe the crystal structure of PRL-1 in comp
254 Here, we describe the crystal structure of the Gn glycop
255 Here, we describe the design and discovery of novel clas
256 Here, we describe the design and synthesis of an ITPA-sp
257 Here, we describe the development and preclinical evalua
258 Here, we describe the development of a flexible thin-fil
259 Here, we describe the development of a generalized linea
260 Here, we describe the development of a programmable CRIS
261 Here, we describe the development of a tiered museum-bas
262 Here, we describe the development of an alternative vacc
263 Here, we describe the development of the first chemilumi
264 Here, we describe the discovery of a splice isoform-depe
265 Here, we describe the discovery of the most potent inhib
266 Here, we describe the engineering of a light-activated h
267 Here, we describe the fabrication, testing and first fie
268 Here, we describe the FEP+ method as applied to protein
269 Here, we describe the first activating mutation in the f
270 Here, we describe the function of the plant homeodomain
271 major mosquito disease vector Aedes aegypti
Here, we describe the generation of multiple stable, tra
272 Here, we describe the generation of transgenic, inducibl
273 Here, we describe the identification of Ms1, a gene prop
274 Here, we describe the latest database release, the IPD-M
275 Here, we describe the map-based cloning of the Ms2 gene
276 Here, we describe the mechanism of action of the previou
277 Here, we describe the mode of action of bimagrumab (BYM3
278 Here, we describe the nature and comparative reactivity
279 Here, we describe the near-atomic resolution structure o
280 Here, we describe the optimization of the 2-anilino quin
281 Here, we describe the rapid and selective thionation of
282 Here, we describe the recent improvements in IRD includi
283 Here, we describe the somatic acquisition of promoter mu
284 Here, we describe the surgical, immunological, and neuro
285 Here, we describe the use of a combined method including
286 Here, we describe the use of fluorescence recovery after
287 Here, we describe the use of PRO-seq to characterize the
288 Here, we describe the use of side-group chemistry to con
289 Here, we describe the use of the B. subtilis model syste
290 Here, we describe the WHO-coordinated laboratory network
291 ongoing studies where clade C predominates,
here we describe three virus panels, chosen from 200 wel
292 Here, we describe three examples to establish that the a
293 Here we describe two advances that address these limitat
294 Here we describe two multi MCE domain-containing protein
295 Here, we describe two brothers with hematopoietic and im
296 Here, we describe two resources developed by the KMC: th
297 Here, we describe two strategies that successfully inves
298 Here, we describe type 2 innate lymphocytes (ILC2s) as a
299 Here we describe utilization of a surface motif exchange
300 Here, we describe why a shared approach to treatment dec